For the year ending 2025-12-31, EXAS had $349,360K increase in cash & cash equivalents over the period. $356,782K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -207,949 |
| Depreciation | 124,879 |
| Equity securities, fv-ni, gain (loss) | 3,081 |
| Deferred tax benefit | -1,544 |
| Share-based payment arrangement, noncash expense | 217,666 |
| Gain on settlements of convertible notes, net | 0 |
| Amortization of intangible assets | 96,700 |
| Impairment of long-lived and indefinite-lived assets | 7,200 |
| Research and development asset acquired in transaction other than business combination or joint venture formation, writeoff | 75,000 |
| Gain (loss) on contingent consideration from disposition of asset | 0 |
| Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability | 26,806 |
| Non-cash lease expense | 27,040 |
| Other noncash income (expense) | -6,896 |
| Accounts receivable, net | 48,891 |
| Inventory, net | 3,772 |
| Operating lease liabilities | -28,541 |
| Accounts payable and accrued liabilities | 214,042 |
| Increase (decrease) in other operating assets | 5,794 |
| Increase (decrease) in other operating liabilities | -5,219 |
| Net cash provided by operating activities | 491,438 |
| Purchases of marketable securities | 140,269 |
| Maturities and sales of marketable securities | 572,277 |
| Purchases of property, plant and equipment | 134,656 |
| Proceeds from contingent consideration receivable | 27,971 |
| Proceeds from sale of investments in privately-held companies | 0 |
| Payments to acquire other investments | 55,499 |
| Business combination, net of cash acquired and issuance costs | 0 |
| Asset acquisitions, net of cash acquired | 75,000 |
| Other investing activities | -297 |
| Net cash provided by (used in) investing activities | 195,121 |
| Proceeds, issuance of shares, share-based payment arrangement, including option exercised | 1,902 |
| Proceeds in connection with the company's employee stock purchase plan | 26,544 |
| Proceeds from issuance of convertible notes | 0 |
| Repayments of accounts receivable securitization | 0 |
| Repayments of convertible debt | 249,172 |
| Payment, tax withholding, share-based payment arrangement | 86,477 |
| Payment for contingent consideration liability, financing activities | 19,000 |
| Other financing activities | -11,887 |
| Net cash provided by (used in) financing activities | -338,090 |
| Effects of exchange rate changes on cash and cash equivalents | 891 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 349,360 |
| Cash and cash equivalents at beginning of period | 606,636 |
| Cash and cash equivalents at end of period | 955,996 |
EXACT SCIENCES CORP (EXAS)
EXACT SCIENCES CORP (EXAS)